Pharmaceuticals
Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited
SHANGHAI, March 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced t...
2021-03-01 12:36
5620
Sciwind's Investigational New Drug Approved for NASH Trial
HANGZHOU, China, March 1, 2021 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd., (Sciwind), a clinical-stage, fast-growing biotech focusing on research and development of innovative biologics, today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatit...
2021-03-01 09:00
3401
Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody
SAN FRANCISCO and SUZHOU, China, March 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-03-01 08:23
7506
Sirtex Medical receives positive recommendation from National Institute for Health and Care Excellence (NICE) for selective internal radiation therapy (SIRT) using SIR-Spheres®
NICE recommends SIR-Spheres® Y-90 microspheres as an option for treating unresectable advanced hepatocellular carcinoma (HCC) in adults WOBURN, Mass., Feb. 26, 2021 /PRNewswire/ -- Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted cancer therapies, received positive...
2021-02-26 23:37
3014
Debiopharm And Genome & Company Join Forces To Create New Highly Specific Therapies For Cancer Patients
Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates LAUSANNE, Switzerland and SEONGNAM-SI GYEONGGI-DO, South Korea, Feb. 26, 2021 /PRNewswire/ -- Genome & Company (CEO:Jisoo Pae, Hanso...
2021-02-26 19:14
4229
Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 26, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HBM4003, the next generati...
2021-02-26 10:16
7710
New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines
DARMSTADT, Germany, Feb. 25, 2021 /PRNewswire/ -- Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced the presentation of a new analysis from the MAGNIFY-MS study on MAVENCLAD® (cladribine tablets) in patients with relapsing multiple sclerosi...
2021-02-25 21:00
3323
Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH
SHANGHAI, Feb. 24, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of nonalcoholic steatohepatitis (NASH), today announces the Investigational New Drug Application (IND) approval ...
2021-02-25 08:30
3824
WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories
SHANGHAI, Feb. 25, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the company has been named a winner of the 2021 CMO Leadership Awards for a fourth year in a row. The company is proud to ...
2021-02-25 08:00
3202
Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI
Insilico Medicine Achieves Industry First Nominating Preclinical Candidate for Idiopathic Pulmonary Fibrosis With Both Novel Drug Target and Novel Molecule Discovered by Artificial Intelligence HONG KONG, Feb. 25, 2021 /PRNewswire/ -- Insilico Medicine has demonstrated a breakthrough in Artifici...
2021-02-25 00:48
3868
First cancer centers begin using initial release of Elekta's MOSAIQ 3 series
ATLANTA, Feb. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that several cancer centers are the early adopters of the company's first release in the MOSAIQ® 3* series. Featuring increased automation and simplified user interfaces, MOSAIQ 3 is designed to significantly reduce workflo...
2021-02-25 00:46
5288
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 326 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 301 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
8004